CYCLOPLATAM THERAPY OF RESISTANT MULTIPLE-MYELOMA

A new drug cycloplatam-platinum compound of the second generation-has been tried in 19 polyresistant (MDR) patients with multiple myeloma (M M). At terminal MM stage 17 patients developed secondary MDR, 2 untrea ted patients appeared to be primarily resistant. Cycloplatam was injec ted intravenously in a dose 60 mg/m(2) in drips per 400 ml of 5% gluco se solution with prednisolone (60 mg per os) combined with hydration a nd antibacterial defense. A total of 42 courses were given. A complete objective response was achieved in 5 of 19 (27.7%) patients, partial response was observed in 1 (5.5%) patient with secondary resistance at terminal MM, 2 (10.5%) patients achieved stabilization. Progression o f the disease occurred in 10 (55.5%) patients with secondary resistanc e at terminal stage. 1 patient died. The remission lasted 16 months so far. There were hematological, gastrointestinal and hepatic side effe cts. All the patients suffered from nausea and vomiting, hematological toxicity (anemia, leukopenia, thrombocytopenia). Hepatic toxicity aff ected only 1 patient.